Product Information
POTASSIUM CITRATE ER 5 MEQ TAB is a generic product labeled by Strides Pharma Inc., priced at $0.1235 per EA under NDC 42543040601. Its NADAC has been published 471 times since Sep 27, 2017.
FDA first approved this application on Sep 11, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 meq/1
Manufacturer
Strides Pharma Inc.NDC
42543040601
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
POTASSIUM CITRATEApproval Type
Generic (ANDA)
FDA Application
ANDA206813FDA Approved
9/11/2017
TE Code
AB
On Market Since
11/1/2017
Pharmacological Classes
Price Statistics
The NADAC for POTASSIUM CITRATE ER 5 MEQ TAB has been published 471 times since Sep 27, 2017, and over the history we have for it it has declined 86.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1235 per EA |
|---|---|
| All-time high | $0.9672 (Nov 15, 2017) |
| All-time low | $0.1064 (May 22, 2024) |
| 52-week high | $0.1419 |
| 52-week low | $0.1217 |
| Median price | $0.4545 |
| Average price | $0.4279 |
| Largest weekly change | +79.1% (Jan 18, 2023) |
| Weeks tracked | 471 |
| Tracking since | Sep 27, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the POTASSIUM CITRATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
POTASSIUM CITRATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-coagulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of POTASSIUM CITRATE ER 5 MEQ TAB?
The current National Average Drug Acquisition Cost (NADAC) for POTASSIUM CITRATE ER 5 MEQ TAB, manufactured by Strides Pharma Inc., is $0.1235 per EA (NDC 42543040601), effective Sep 30, 2026.
How has the price of POTASSIUM CITRATE ER 5 MEQ TAB changed over time?
Over the history we have for it, the NADAC for POTASSIUM CITRATE ER 5 MEQ TAB has declined 86.4%. It has been tracked across 471 weekly CMS publications since Sep 27, 2017.
What are the highest and lowest recorded NADAC prices for POTASSIUM CITRATE ER 5 MEQ TAB?
Since Sep 27, 2017, the NADAC for POTASSIUM CITRATE ER 5 MEQ TAB has ranged from a low of $0.1064 (May 22, 2024) to a high of $0.9672 (Nov 15, 2017), with a median of $0.4545 per EA.
Are there cheaper alternatives to POTASSIUM CITRATE ER 5 MEQ TAB?
No other NADAC-published product currently shares the active ingredient and strength of POTASSIUM CITRATE ER 5 MEQ TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures POTASSIUM CITRATE ER 5 MEQ TAB?
POTASSIUM CITRATE ER 5 MEQ TAB (NDC 42543040601) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.